Pfizer Inc (PFE.N)
23 Oct 2014
|Market Cap (Mil.):||$181,348.70|
|Shares Outstanding (Mil.):||6,340.86|
LONDON/NEW YORK - U.S. drugmaker Pfizer is to continue buying back stock, with the board authorizing a new $11 billion share repurchase plan, deflating expectations that it will make a new bid for AstraZeneca.
Oct 23 - Pfizer Inc on Thursday said its board of directors has authorized an $11 billion share repurchase program to be utilized over time.
- A U.S. district court ruled in favor of Pfizer Inc in a patent lawsuit it filed against Mylan Inc alleging patent infringement on its cancer drug, Sutent, Pfizer said.
Oct 23 - A U.S. district court ruled in favor of Pfizer Inc in a patent lawsuit it filed against Mylan Inc alleging patent infringement on its cancer drug, Sutent, Pfizer said.
* Governments or multilateral agencies may offer indemnity
- Pfizer Inc failed to convince the U.S. Food and Drug Administration to remove a black box warning on its controversial quit-smoking drug Chantix, with an advisory panel to the agency voting against the removal on Thursday.
Oct 16 - Pfizer Inc failed to convince the U.S. Food and Drug Administration to remove a black box warning on its controversial quit-smoking drug Chantix, with an advisory panel to the agency voting against the removal on Thursday.
Oct 16 - Pfizer Inc failed in its attempt to remove a black box warning from its controversial quit-smoking drug, Chantix, after an advisory panel to the U.S. Food and Drug Administration voted against the removal.
LONDON - A decision by U.S. drugmaker AbbVie to scrap its plans to buy Dublin-based Shire could mean that bankers miss out on up to $135 million in fees linked to the deal.
NEW YORK, Oct 15 - A federal judge in Manhattan will soon have to weigh in on how the family of a convicted insider trader should live while the man spends nearly a decade in federal prison.
|Johnson & Johnson (JNJ.N)||$102.63||+1.41|
|Novartis AG (NOVN.VX)||CHF85.50||+0.10|
|Merck & Co., Inc. (MRK.N)||$56.63||+1.12|
|Roche Holding Ltd. (ROG.VX)||CHF278.30||-1.10|
|Abbott Laboratories (ABT.N)||$42.43||+0.84|
|Bayer AG (BAYGn.DE)||€95.41||-2.28|
|Bayer AG (BAYE.F)||--||--|
|Sanofi SA (SASY.PA)||€84.75||-0.15|
|AstraZeneca plc (AZN.L)||4,302.64p||-33.00|
|GlaxoSmithKline plc (GSK.L)||1,423.50p||+11.50|
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (PFE). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Provider: Thomson Reuters Stock Report
Provider: New Constructs, LLC
"The Economy Matters" Report for PFE: the economy's impact on PFE's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.